The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil
Identifieur interne : 002776 ( Main/Curation ); précédent : 002775; suivant : 002777The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil
Auteurs : W. Birkmayer [Autriche] ; P. Riederer [Autriche] ; H. Youdim [Autriche] ; W. Linauer [Autriche]Source :
- Journal of Neural Transmission [ 0300-9564 ] ; 1975-09-01.
Abstract
Summary: The potentiation of the ami akinetic effect after L-Dopa treatment by an inhibitor of monoamine oxidase (MAO) “B”, Deprenil, has been demonstrated in parkinsonian patients with or without previous L-Dopa therapy. Application of the drug has been performed orally, intravenously and intramuscularly. Excellent kinetic effects resulted when combined with Madopar. The combined treatment with L-Dopa was highly effective when applicated i.v. or i.m. Deprenil is an inhibitor of MAO-B and is characterized by less frequent side effects. These are predominantly involuntary movements and confusion, which can be eliminated by lowering the dosage of Deprenil. A daily rhythm of MAO could be demonstrated in several areas of human brains as well in a control group as in parkinsonian patients with or without L-Dopa therapy. Maximal activity of MAO occurs between noon and 6 p.m. The clinical and biochemical data are discussed regarding the off-phenomenons as Deprenil is an excellent drug for preventing these.
Url:
DOI: 10.1007/BF01253131
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002B41
Links to Exploration step
ISTEX:8A8E8BAC0EEF481EE5435F92234EB5AEB2D7B0F2Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil</title>
<author><name sortKey="Birkmayer, W" sort="Birkmayer, W" uniqKey="Birkmayer W" first="W." last="Birkmayer">W. Birkmayer</name>
<affiliation wicri:level="1"><mods:affiliation>Ludwig-Boltzmann-Institut für Neurochemie, Geriatrisches Krankenhaus der Stadt Wien-Lainz, Austria</mods:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Ludwig-Boltzmann-Institut für Neurochemie, Geriatrisches Krankenhaus der Stadt Wien-Lainz</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Riederer, P" sort="Riederer, P" uniqKey="Riederer P" first="P." last="Riederer">P. Riederer</name>
<affiliation wicri:level="1"><mods:affiliation>Ludwig-Boltzmann-Institut für Neurochemie, Geriatrisches Krankenhaus der Stadt Wien-Lainz, Austria</mods:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Ludwig-Boltzmann-Institut für Neurochemie, Geriatrisches Krankenhaus der Stadt Wien-Lainz</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Youdim, H" sort="Youdim, H" uniqKey="Youdim H" first="H." last="Youdim">H. Youdim</name>
<affiliation wicri:level="1"><mods:affiliation>Ludwig-Boltzmann-Institut für Neurochemie, Geriatrisches Krankenhaus der Stadt Wien-Lainz, Austria</mods:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Ludwig-Boltzmann-Institut für Neurochemie, Geriatrisches Krankenhaus der Stadt Wien-Lainz</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Linauer, W" sort="Linauer, W" uniqKey="Linauer W" first="W." last="Linauer">W. Linauer</name>
<affiliation wicri:level="1"><mods:affiliation>Ludwig-Boltzmann-Institut für Neurochemie, Geriatrisches Krankenhaus der Stadt Wien-Lainz, Austria</mods:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Ludwig-Boltzmann-Institut für Neurochemie, Geriatrisches Krankenhaus der Stadt Wien-Lainz</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:8A8E8BAC0EEF481EE5435F92234EB5AEB2D7B0F2</idno>
<date when="1975" year="1975">1975</date>
<idno type="doi">10.1007/BF01253131</idno>
<idno type="url">https://api.istex.fr/document/8A8E8BAC0EEF481EE5435F92234EB5AEB2D7B0F2/fulltext/pdf</idno>
<idno type="wicri:Area/Main/Corpus">002B41</idno>
<idno type="wicri:Area/Main/Curation">002776</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil</title>
<author><name sortKey="Birkmayer, W" sort="Birkmayer, W" uniqKey="Birkmayer W" first="W." last="Birkmayer">W. Birkmayer</name>
<affiliation wicri:level="1"><mods:affiliation>Ludwig-Boltzmann-Institut für Neurochemie, Geriatrisches Krankenhaus der Stadt Wien-Lainz, Austria</mods:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Ludwig-Boltzmann-Institut für Neurochemie, Geriatrisches Krankenhaus der Stadt Wien-Lainz</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Riederer, P" sort="Riederer, P" uniqKey="Riederer P" first="P." last="Riederer">P. Riederer</name>
<affiliation wicri:level="1"><mods:affiliation>Ludwig-Boltzmann-Institut für Neurochemie, Geriatrisches Krankenhaus der Stadt Wien-Lainz, Austria</mods:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Ludwig-Boltzmann-Institut für Neurochemie, Geriatrisches Krankenhaus der Stadt Wien-Lainz</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Youdim, H" sort="Youdim, H" uniqKey="Youdim H" first="H." last="Youdim">H. Youdim</name>
<affiliation wicri:level="1"><mods:affiliation>Ludwig-Boltzmann-Institut für Neurochemie, Geriatrisches Krankenhaus der Stadt Wien-Lainz, Austria</mods:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Ludwig-Boltzmann-Institut für Neurochemie, Geriatrisches Krankenhaus der Stadt Wien-Lainz</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Linauer, W" sort="Linauer, W" uniqKey="Linauer W" first="W." last="Linauer">W. Linauer</name>
<affiliation wicri:level="1"><mods:affiliation>Ludwig-Boltzmann-Institut für Neurochemie, Geriatrisches Krankenhaus der Stadt Wien-Lainz, Austria</mods:affiliation>
<country xml:lang="fr">Autriche</country>
<wicri:regionArea>Ludwig-Boltzmann-Institut für Neurochemie, Geriatrisches Krankenhaus der Stadt Wien-Lainz</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Journal of Neural Transmission</title>
<title level="j" type="sub">Basic neurosciences and genetics, Parkinson's disease and allied conditions, Alzheimer's disease and related disorders, biological psychiatry</title>
<title level="j" type="abbrev">J. Neural Transmission</title>
<idno type="ISSN">0300-9564</idno>
<idno type="eISSN">1435-1463</idno>
<imprint><publisher>Springer-Verlag</publisher>
<pubPlace>Vienna</pubPlace>
<date type="published" when="1975-09-01">1975-09-01</date>
<biblScope unit="volume">36</biblScope>
<biblScope unit="issue">3-4</biblScope>
<biblScope unit="page" from="303">303</biblScope>
<biblScope unit="page" to="326">326</biblScope>
</imprint>
<idno type="ISSN">0300-9564</idno>
</series>
<idno type="istex">8A8E8BAC0EEF481EE5435F92234EB5AEB2D7B0F2</idno>
<idno type="DOI">10.1007/BF01253131</idno>
<idno type="ArticleID">Art10</idno>
<idno type="ArticleID">BF01253131</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0300-9564</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass></textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Summary: The potentiation of the ami akinetic effect after L-Dopa treatment by an inhibitor of monoamine oxidase (MAO) “B”, Deprenil, has been demonstrated in parkinsonian patients with or without previous L-Dopa therapy. Application of the drug has been performed orally, intravenously and intramuscularly. Excellent kinetic effects resulted when combined with Madopar. The combined treatment with L-Dopa was highly effective when applicated i.v. or i.m. Deprenil is an inhibitor of MAO-B and is characterized by less frequent side effects. These are predominantly involuntary movements and confusion, which can be eliminated by lowering the dosage of Deprenil. A daily rhythm of MAO could be demonstrated in several areas of human brains as well in a control group as in parkinsonian patients with or without L-Dopa therapy. Maximal activity of MAO occurs between noon and 6 p.m. The clinical and biochemical data are discussed regarding the off-phenomenons as Deprenil is an excellent drug for preventing these.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002776 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 002776 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= ParkinsonV1 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:8A8E8BAC0EEF481EE5435F92234EB5AEB2D7B0F2 |texte= The potentiation of the anti akinetic effect after L-Dopa treatment by an inhibitor of Mao-B, deprenil }}
This area was generated with Dilib version V0.6.23. |